Literature DB >> 28425480

Efficient CNS targeting in adult mice by intrathecal infusion of single-stranded AAV9-GFP for gene therapy of neurological disorders.

K Bey1,2,3, C Ciron1,2,3, L Dubreil1,2,3, J Deniaud1,2,3, M Ledevin1,2,3, J Cristini4, V Blouin5, P Aubourg6, M-A Colle1,2,3.   

Abstract

Adeno-associated virus (AAV) gene therapy constitutes a powerful tool for the treatment of neurodegenerative diseases. While AAVs are generally administered systemically to newborns in preclinical studies of neurological disorders, in adults the maturity of the blood-brain barrier (BBB) must be considered when selecting the route of administration. Delivery of AAVs into the cerebrospinal fluid (CSF) represents an attractive approach to target the central nervous system (CNS) and bypass the BBB. In this study, we investigated the efficacy of intra-CSF delivery of a single-stranded (ss) AAV9-CAG-GFP vector in adult mice via intracisternal (iCist) or intralumbar (it-Lumb) administration. It-Lumb ssAAV9 delivery resulted in greater diffusion throughout the entire spinal cord and green fluorescent protein (GFP) expression mainly in the cerebellum, cortex and olfactory bulb. By contrast, iCist delivery led to strong GFP expression throughout the entire brain. Comparison of the transduction efficiency of ssAAV9-CAG-GFP versus ssAAV9-SYN1-GFP following it-Lumb administration revealed widespread and specific GFP expression in neurons and motoneurons of the spinal cord and brain when the neuron-specific synapsin 1 (SYN1) promoter was used. Our findings demonstrate that it-Lumb ssAAV9 delivery is a safe and highly efficient means of targeting the CNS in adult mice.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28425480     DOI: 10.1038/gt.2017.18

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  45 in total

Review 1.  Alzheimer's disease.

Authors:  Henry W Querfurth; Frank M LaFerla
Journal:  N Engl J Med       Date:  2010-01-28       Impact factor: 91.245

Review 2.  Parkinson's disease.

Authors:  Lorraine V Kalia; Anthony E Lang
Journal:  Lancet       Date:  2015-04-19       Impact factor: 79.321

3.  Adeno-associated virus-mediated gene transfer to the neonatal brain.

Authors:  Jing Li; Thomas M Daly
Journal:  Methods       Date:  2002-10       Impact factor: 3.608

4.  Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates.

Authors:  Kathrin Meyer; Laura Ferraiuolo; Leah Schmelzer; Lyndsey Braun; Vicki McGovern; Shibi Likhite; Olivia Michels; Alessandra Govoni; Julie Fitzgerald; Pablo Morales; Kevin D Foust; Jerry R Mendell; Arthur H M Burghes; Brian K Kaspar
Journal:  Mol Ther       Date:  2014-10-31       Impact factor: 11.454

5.  Characterization of genome integrity for oversized recombinant AAV vector.

Authors:  Biao Dong; Hiroyuki Nakai; Weidong Xiao
Journal:  Mol Ther       Date:  2009-11-10       Impact factor: 11.454

6.  Human alpha-iduronidase gene transfer mediated by adeno-associated virus types 1, 2, and 5 in the brain of nonhuman primates: vector diffusion and biodistribution.

Authors:  Carine Ciron; Arnaud Cressant; Françoise Roux; Sylvie Raoul; Yan Cherel; Philippe Hantraye; Nicole Déglon; Bertrand Schwartz; Martine Barkats; Jean-Michel Heard; Marc Tardieu; Philippe Moullier; Marie-Anne Colle
Journal:  Hum Gene Ther       Date:  2009-04       Impact factor: 5.695

Review 7.  Spinal muscular atrophy--recent therapeutic advances for an old challenge.

Authors:  Irene Faravelli; Monica Nizzardo; Giacomo P Comi; Stefania Corti
Journal:  Nat Rev Neurol       Date:  2015-05-19       Impact factor: 42.937

8.  Systemic AAVrh10 provides higher transgene expression than AAV9 in the brain and the spinal cord of neonatal mice.

Authors:  Yannick Tanguy; Maria G Biferi; Aurore Besse; Stephanie Astord; Mathilde Cohen-Tannoudji; Thibaut Marais; Martine Barkats
Journal:  Front Mol Neurosci       Date:  2015-07-28       Impact factor: 5.639

Review 9.  The established and emerging roles of astrocytes and microglia in amyotrophic lateral sclerosis and frontotemporal dementia.

Authors:  Rowan A Radford; Marco Morsch; Stephanie L Rayner; Nicholas J Cole; Dean L Pountney; Roger S Chung
Journal:  Front Cell Neurosci       Date:  2015-10-27       Impact factor: 5.505

10.  AAV9-mediated central nervous system-targeted gene delivery via cisterna magna route in mice.

Authors:  Vera Lukashchuk; Katherine E Lewis; Ian Coldicott; Andrew J Grierson; Mimoun Azzouz
Journal:  Mol Ther Methods Clin Dev       Date:  2016-02-17       Impact factor: 6.698

View more
  23 in total

Review 1.  Genome engineering for CNS injury and disease.

Authors:  Jennifer Pardieck; Shelly Sakiyama-Elbert
Journal:  Curr Opin Biotechnol       Date:  2018-03-27       Impact factor: 9.740

2.  Slow Infusion of Recombinant Adeno-Associated Viruses into the Mouse Cerebrospinal Fluid Space.

Authors:  Dan Wang; Jia Li; Karen Tran; Daniel R Burt; Li Zhong; Guangping Gao
Journal:  Hum Gene Ther Methods       Date:  2018-03-29       Impact factor: 2.396

Review 3.  Gene therapy for Mucopolysaccharidoses.

Authors:  Kazuki Sawamoto; Hui-Hsuan Chen; Carlos J Alméciga-Díaz; Robert W Mason; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2017-12-26       Impact factor: 4.797

4.  Treatment of a Mouse Model of ALS by In Vivo Base Editing.

Authors:  Colin K W Lim; Michael Gapinske; Alexandra K Brooks; Wendy S Woods; Jackson E Powell; M Alejandra Zeballos C; Jackson Winter; Pablo Perez-Pinera; Thomas Gaj
Journal:  Mol Ther       Date:  2020-01-14       Impact factor: 11.454

5.  Biodistribution of Adeno-Associated Virus Serotype 5 Viral Vectors Following Intrathecal Injection.

Authors:  Kelsey R Pflepsen; Cristina D Peterson; Kelley F Kitto; Maureen S Riedl; R Scott McIvor; George L Wilcox; Lucy Vulchanova; Carolyn A Fairbanks
Journal:  Mol Pharm       Date:  2021-08-30       Impact factor: 5.364

6.  A splice-site variant in FLVCR1 produces retinitis pigmentosa without posterior column ataxia.

Authors:  Imran H Yusuf; Morag E Shanks; Penny Clouston; Robert E MacLaren
Journal:  Ophthalmic Genet       Date:  2017-12-01       Impact factor: 1.803

7.  Viral Vector Technologies and Strategies: Improving on Nature.

Authors:  Roxanne H Croze; Melissa Kotterman; Christian H Burns; Chris E Schmitt; Melissa Quezada; David Schaffer; David Kirn; Peter Francis
Journal:  Int Ophthalmol Clin       Date:  2021-07-01

8.  Screening for gene doping transgenes in horses via the use of massively parallel sequencing.

Authors:  Jillian Maniego; Bogusia Pesko; Jocelyn Habershon-Butcher; Jim Huggett; Polly Taylor; James Scarth; Edward Ryder
Journal:  Gene Ther       Date:  2021-07-19       Impact factor: 5.250

Review 9.  Adeno-Associated Viral Vectors as Versatile Tools for Parkinson's Research, Both for Disease Modeling Purposes and for Therapeutic Uses.

Authors:  Ana Fajardo-Serrano; Alberto J Rico; Elvira Roda; Adriana Honrubia; Sandra Arrieta; Goiaz Ariznabarreta; Julia Chocarro; Elena Lorenzo-Ramos; Alvaro Pejenaute; Alfonso Vázquez; José Luis Lanciego
Journal:  Int J Mol Sci       Date:  2021-06-15       Impact factor: 5.923

10.  Adeno-associated virus-mediated delivery of CRISPR-Cas9 for genome editing in the central nervous system.

Authors:  Christina M Fuentes; David V Schaffer
Journal:  Curr Opin Biomed Eng       Date:  2018-08-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.